Advertisement


Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Advertisement